All
Honoring a Healer: Personal Care With National Impact
This is a joint nomination by Camille Moses and Dr. Estelamari Rodriguez.
Breaking Barriers: Why Increasing Lung Screening is Critical
Lung cancer remains the leading cause of cancer-related deaths in the U.S.
Lung Cancer Initiative Names New Chief Scientific Officer and Announces 2025 Research Award Recipients
LCI has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer.
Managing Lung Inflammation After Chemoradiation and Tagrisso
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
LCI Shows Support for Lung Cancer Research Funding at GO2 Voices Summit
Lung Cancer Initiative proudly participated in the GO2 Voices Summit held March 9–11, 2025, in Washington, DC.
How Quitting Smoking After a Cancer Diagnosis Can Boost Survival
Dr. Daniel J. Boffa discusses the link between smoking cessation and increase in survival for people who are active smokers and diagnosed with cancer.
A Nurse Who Became Family After a Cancer Diagnosis
Eric Z. cared for my sister and mentored me with compassion, wisdom and unwavering presence — shaping my path in nursing and life.
Cemsidomide Generates Results at Multiple Doses in Multiple Myeloma
Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma
Enhertu Regimen Improves Responses in High-Risk HER2+ Breast Cancer
Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk HER2-positive early-stage breast cancer.
Breast Cancer Survivor Reflects on 30 Years, Urges Informed Decisions
After 30 years with breast cancer, I urge others to pause, reflect and choose care based on long-term wellbeing, not fear or pressure.
Fighting for Patients, Processes and Education
I would like to nominate Ashley Tullio, RN, for the Extraordinary Healer Award for Oncology Nursing.
The Importance of Personalized Treatment Approaches for Urologic Cancers
Dr. Armine Smith discusses the importance of personalized therapeutic approaches for the treatment of urologic cancers, such as bladder or kidney cancer.
Nurse’s Big Personality Makes Cancer Treatment More Bearable.
She wore a variety of bright sneakers and occasionally did a cha-cha-cha in them. Her laughter was contagious. Patients smiled. The other nurses smiled.
Givinostat Wins U.S. FDA Fast Track Designation for Patients With PV
Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for patients with polycythemia vera.
First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo
The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.
Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC
Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.
A Staunch Advocate For Radiation Oncology Nursing and Compassionate Care
Everyone knows someone who has been affected by cancer.
A Personalized Approach to Bladder Preservation in Urologic Cancers
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
Mitigating Peripheral Neuropathy During Cancer Treatment
Dr. Shirley D'Sa discusses the importance of catching peripheral neuropathy in patients with Waldenstrom macroglobulinemia early on, and how to treat it.
My Lung Cancer Journey: With Family, Friends and Medical Professionals
The strongest connections I’ve made are with others who have also been through their own cancer journeys.
AI Tool Predicts Pediatric Glioma Recurrence With Up to 89% Accuracy
An AI model using serial brain scans predicted glioma recurrence in children with up to 89% accuracy, outperforming single-image methods.
First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
Cancer Survivor Raises AYA Awareness After Rare Lymphoma Diagnosis
In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support for young adults with cancer.
POIESIS Trial Explores Navtemadlin Plus Jakafi for Myelofibrosis
The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.
An Expert Offers Advice and Resources for Navigating Rare Lymphoma
Dr. Neha Mehta-Shah shares how patients can better understand their subtype of rare lymphoma, as well as expands on the challenges these patients face.
Celebrating an Expert at Emotional Support
It is with great pride and admiration that I nominate Diane Hudson, RN, OCN, for the Extraordinary Healer Award for Oncology Nursing.
Dr. Eng Breaks Down Braftovi Plus Erbitux FDA Approval in BRAF+ mCRC
Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic colorectal cancer.
A Healer’s Touch During My Experience With Cancer Care
The Calm of Unbroken Kindness
The nursing profession is home to countless extraordinary.
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care
Dr. Scott T. Tagawa discusses what patients with prostate cancer should know about the potential benefits and risks of participating in a clinical trial.
